Riding an AH revenue growth trend?........ Are Merck's just-released Q2-12 results (with focus on their Animal Health revenue) a good indicator of what to expect of BNC's AH revenue year-end results (released on Sep12-12)? They seemed to be a good indicator last quarter. Note: Bayer also releases its quarterly results next Tuesday.
The following is an excerpt from link below to Merck's Q2 results just released:
Animal Health Revenue Performance
Animal Health sales totaled $865 million for the second quarter of 2012, an 8 percent increase over the second quarter of 2011, including a 6 percent negative impact due to foreign exchange. Animal Health had strong performance in the United States and Asia Pacific, with growth led by increased sales of cattle and swine products. The division's products include pharmaceutical and vaccine products for the prevention, treatment and control of disease in all major farm and companion animal species.
And, as you recall...here's where Bioniche's AH division results were as at Q3-12 (an excerpt from a previous post after last qutr's release). Hopefully, we see more of this growth!
- sales of Animal Health products 10% ahead of Fiscal 2011 on a year-to-date basis -
...and, versus same quarter last year, the revenue for AH division is + 16.7%* qtr/qtr with continued solid margins.
That's two back-to-back quarters with strong revenue growth for AH division. Q3: +17% and Q2: +21%
Appears the new distribution agreements and new product launches in fiscal 2011 are beginning to pay-off for this division.
rg